In the present study, we evaluated plasma levels of the prototypical acute phase protein CRP, Interleukin-1 receptor antagonist (IL-1Ra) which is synthesized and released by activated monocyte-macrophages at sites of tissue damageyinflammation and Interleukin-2 soluble receptor (sIL-2R), a specific marker of T-lymphocyte activation, in patients with mild ischaemic LVD.
